What is the price target for NAMS stock?
21 analysts have analysed NAMS and the average price target is 50.53 USD. This implies a price increase of 68.99% is expected in the next year compared to the current price of 29.9.
NEWAMSTERDAM PHARMA CO NV (NAMS) Forecast, Price Target & Analyst Ratings
NASDAQ:NAMS • NL00150012L7
Current stock price
29.9 USD
+0.46 (+1.56%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEWAMSTERDAM PHARMA CO NV (NAMS).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.50
- Revenue Estimate
- 955.087K
Price Target Details & History
Consensus Price Target and Range
Mean target
$50.53
Upside
+ 68.99%
From current price of $29.90 to mean target of $50.53, Based on 21 analyst forecasts
Low
$38.38
Median
$49.98
High
$63.00
Price Target Revisions
1 Month
15.88%
3 Months
15.88%
Price Target Summary
21 Wall Street analysts provided a forecast for the next 12 months for NAMS. The average price target is 50.53 USD. This implies a price increase of 68.99% is expected in the next year compared to the current price of 29.9.
The average price target has been revised upward by 15.88% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.67%
NAMS was analyzed by 21 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about NAMS.
In the previous month the buy percentage consensus was at a similar level.
NAMS was analyzed by 21 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-19 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-18 | Needham | Maintains | Buy -> Buy |
| 2026-01-21 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-16 | Stifel | Maintains | Buy -> Buy |
| 2025-12-02 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-11-06 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-05 | Needham | Maintains | Buy -> Buy |
| 2025-10-17 | Citigroup | Maintains | Buy -> Buy |
| 2025-08-25 | Wells Fargo | Initiate | Overweight |
| 2025-08-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-17 | Goldman Sachs | Initiate | Neutral |
| 2025-06-17 | Citigroup | Initiate | Buy |
| 2025-06-12 | Needham | Reiterate | Buy -> Buy |
| 2025-06-10 | Stifel | Initiate | Buy |
| 2025-05-08 | Needham | Maintains | Buy -> Buy |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-02-27 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-02-27 | Needham | Maintains | Buy -> Buy |
| 2025-01-28 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-01-24 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-30 | HC Wainwright & Co. | Initiate | Buy |
| 2024-12-11 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-12-05 | Needham | Reiterate | Buy -> Buy |
| 2024-11-21 | Needham | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.50
- Revenue Estimate
- 955.087K
- Revenue Q2Q
- -67.93%
- EPS Q2Q
- -47.69%
- Number of Analysts
- 16
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
NAMS is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.5 USD and the consensus revenue estimate is 955.09K USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 97.5M | 13.254M -86.41% | 32.622M 146.13% | 27.957M -14.30% | 27.647M -1.11% | 169.7M 513.81% | 424.1M 149.91% | 778.76M 83.63% | 1.169B 50.11% | 1.364B 16.68% | 1.618B 18.62% | 1.998B 23.49% | |||
| EBITDA YoY % growth | -126.7K | -1.352M -967.32% | -3.867M -185.96% | -218.688M -5,555.24% | -192.78M 11.85% | -214.205M -11.11% | -241.42M -12.71% | 9.875M 104.09% | 387.33M 3,822.33% | 1.413B 264.81% | 1.65B 16.77% | N/A | N/A | N/A | |
| EBIT YoY % growth | -127.7K | -1.366M -969.93% | -3.939M -188.30% | -192.371M -4,783.75% | -190.345M 1.05% | -212.006M -11.38% | -259.017M -22.17% | -183.838M 29.02% | 86.744M 147.19% | 300.83M 246.80% | 678.85M 125.66% | 821.6M 21.03% | 976.64M 18.87% | 1.287B 31.78% | |
| Operating Margin | N/A | N/A | -4.04% | -1,451.42% | -583.49% | -758.33% | -936.87% | -108.33% | 20.45% | 38.63% | 58.07% | 60.23% | 60.36% | 64.41% | |
| EPS YoY % growth | N/A | N/A | N/A | -2.21 -1,306.89% | -2.12 -16.91% | -1.53 33.33% | -2.04 -18.57% | -1.37 33.02% | -0.24 82.78% | 1.44 712.45% | 3.49 142.08% | 3.81 9.20% | 5.10 34.04% | 6.25 22.37% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.50 -47.69% | -0.51 -238.69% | -0.49 20.03% | -0.47 24.51% | -0.52 -3.60% | -0.53 -4.40% | -0.43 11.48% | -0.17 63.68% |
| Revenue Q2Q % growth | 955.087K -67.93% | 1.386M -92.76% | 8.778M 2,422.41% | 18.375M 57,321.88% | 4.077M 326.87% | 6.715M 384.49% | 28.91M 229.35% | 75.579M 311.31% |
| EBITDA Q2Q % growth | -69.451M | -66.726M | -54.412M -20.71% | -49.183M 7.47% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -55.559M 4.38% | -56.267M 13.74% | -52.404M 1.73% | -50.719M 3.47% | -72.212M -29.97% | -70.879M -25.97% | -48.83M 6.82% | 8.114M 116.00% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
NEWAMSTERDAM PHARMA CO NV / NAMS Forecast FAQ
What is the next earnings date for NAMS stock?
NEWAMSTERDAM PHARMA CO NV (NAMS) will report earnings on 2026-05-06, before the market open.
Can you provide the consensus estimates for NEWAMSTERDAM PHARMA CO NV next earnings?
The consensus EPS estimate for the next earnings of NEWAMSTERDAM PHARMA CO NV (NAMS) is -0.5 USD and the consensus revenue estimate is 955.09K USD.
How many analysts have analysed NEWAMSTERDAM PHARMA CO NV (NAMS)?
The number of analysts covering NEWAMSTERDAM PHARMA CO NV (NAMS) is 21.